Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH22162 in Essential Hypertension
NCT02620163Phase 3Completed
- Sponsor
- Yuhan
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of telmisartan + amlodipine + chlorthalidone in essential hypertension, sponsored by Yuhan. Started Dec 2015; status: completed.
02
Drugs
telmisartan + amlodipine + chlorthalidone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02620163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620163.